Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Ticker SymbolPHVS
CompanyPharvaris NV
CEOModig (Berndt B.A.E)
Websitehttps://pharvaris.com/
FAQs
What is the current price of Pharvaris NV (PHVS)?
The current price of Pharvaris NV (PHVS) is 25.630.
What is the symbol of Pharvaris NV?
The ticker symbol of Pharvaris NV is PHVS.
What is the 52-week high of Pharvaris NV?
The 52-week high of Pharvaris NV is 29.797.
What is the 52-week low of Pharvaris NV?
The 52-week low of Pharvaris NV is 11.510.
What is the market capitalization of Pharvaris NV?
The market capitalization of Pharvaris NV is 1.66B.
What is the net income of Pharvaris NV?
The net income of Pharvaris NV is -100.88M.
Is Pharvaris NV (PHVS) currently rated as Buy, Hold, or Sell?
According to analysts, Pharvaris NV (PHVS) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of Pharvaris NV (PHVS)?
The Earnings Per Share (EPS TTM) of Pharvaris NV (PHVS) is -2.338.